Description
A site dedicated to the cancer drug class targeting Heat Shock Protein 90 (HSP90). Featuring drug discovery, clinical development, business transaction, conference presentations, etc related to these drugs including ganetespib, AT13387, retaspimycin, 17-AAG and more.
HSP90 Inhibitors Central's Latest Posts
+
The HSP90 Central blog has been your source for updates on the rebirth of HSP90 inhibitor candidate SNX-5422 and its development by former Serenex executives working at newly formed Esanex. Here are the latest updates: [...]
+
We now have our first look at the upcoming data at the 2013 ASCO Annual Meeting related to HSP90 inhibitors in development in various cancers. Full abstracts with data will be released May 15th.The key focus will be on ganetespib (Synta Pharma SNTA), with data also to come on AUY922 (Novartis) and [...]
+
It is that time again.... the annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner in early June. Abstracts will be released May 15th, so we will begin to feature key presentations both here at HSP90 Central and at BiotechDueDiligence.First up? The ALK inhibitors. This post features presentations related t [...]
+
Ariad Pharmaceuticals ARIA issued a corporate update press release today (4/4/2013). The main focused was CML drug ICLUSIG (ponatinib), but there were also more updates, discussion, and color regarding their ALK/EGFR inhibitor AP26113 than I expected. Therefore, I'll summarize these below along with any additional color from the conference call. [...]
+
If you enjoyed the recent HSP90-related AACR preview posts, be sure to also visit the sister site BiotechDueDiligence for several more AACR preview editions this week, and more coverage from the conference April 6-10th. [...]
Tags
